Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA)

Historical Holders from Q3 2020 to Q3 2025

Symbol
TSHA on Nasdaq
CUSIP
877619106
Type / Class
Equity / Common Stock, $0.00001 par value
Shares outstanding
275M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
264M
Holdings value
$865M
% of all portfolios
0.007%
Grand Portfolio weight change
+0%
Number of holders
149
Number of buys
85
Number of sells
-55
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 9.9% 0% $90.5M $7.57M 27.7M +9.14% RA Capital Management, L.P. Sep 30, 2025
Manning Paul B 9.8% $59.4M 25.6M Paul B Manning May 30, 2025
RTW INVESTMENTS, LP 9.9% -0.9% $66.5M $11.9M 25.2M +21.8% RTW Investments, LP Jun 30, 2025
MORGAN STANLEY 6.7% -21.1% $44.5M -$2.03M 16.9M -4.37% Morgan Stanley Jun 30, 2025
FMR LLC 6.2% -22.5% $41.3M -$1.95M 15.6M -4.51% FMR LLC Jun 30, 2025
BlackRock, Inc. 5.2% $30.4M 13.2M BlackRock, Inc. Jun 30, 2025
GOLDMAN SACHS GROUP INC 5.1% $33.3M 12.7M THE GOLDMAN SACHS GROUP, INC. Jun 26, 2025
Octagon Capital Advisors LP 3.3% -36% $29.7M -$4.52M 9.07M -13.2% Octagon Capital Advisors LP Sep 30, 2025

Institutional Holders of Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 264M $865M +$29.3M $3.27 149
2025 Q2 258M $595M +$212M $2.31 147
2025 Q1 167M $232M -$5.17M $1.39 124
2024 Q4 167M $289M +$19M $1.73 125
2024 Q3 157M $315M -$17.6M $2.01 114
2024 Q2 158M $354M +$33.9M $2.24 102
2024 Q1 140M $402M +$33.4M $2.87 106
2023 Q4 130M $230M -$12.3M $1.77 85
2023 Q3 130M $410M +$376M $3.16 61
2023 Q2 13.7M $9.05M -$2.01M $0.66 37
2023 Q1 16.7M $13.3M -$3.03M $0.80 42
2022 Q4 19.4M $43.8M +$12.4M $2.26 51
2022 Q3 13.9M $27M -$1.81M $1.93 49
2022 Q2 14.7M $54.7M -$11.6M $3.72 55
2022 Q1 17M $111M -$16.2M $6.52 70
2021 Q4 18.5M $216M -$15.4M $11.65 64
2021 Q3 19.4M $362M +$4.4M $18.62 48
2021 Q2 18.3M $388M +$15M $21.20 48
2021 Q1 17.7M $359M -$11.6M $20.30 46
2020 Q4 18M $475M +$32M $26.54 51
2020 Q3 16.6M $367M +$367M $22.40 46